Orchid Pharma Limited
NSE: ORCHPHARMA | BSE: 524372 | Sector: Pharmaceuticals – API/Formulations | Small-Cap
Business Overview
Orchid Pharma Limited is a Chennai-based pharmaceutical company engaged in the manufacture of active pharmaceutical ingredients (APIs) and finished dosage formulations, with a core focus on Cephalosporin-based APIs used in anti-bacterial, anti-inflammatory and CNS/CVS formulations. The company came under the ownership of Dhanuka Laboratories Limited via an NCLT-approved resolution plan effective March 2020, and the two entities were subsequently amalgamated through a Scheme of Arrangement; final share allotment to Dhanuka Laboratories shareholders was completed on August 1, 2026, taking paid-up capital to ₹59.89 Cr. In 2025 the company launched its Antimicrobial Solutions (AMS) division targeting the antimicrobial-resistance (AMR) opportunity, and has signed agreements to acquire assets of Germany/France-based Allecra Therapeutics, adding the novel antibiotic Cefepime-Enmetazobactam to its portfolio. Promoter holding stands at 69.84%. FY26 was a weak year operationally — consolidated revenue fell to ₹811 Cr (down ~12% YoY) and OPM compressed sharply to ~5% from ~13% in FY25, with two quarters (Sep’25, Dec’25) reporting operating losses before a partial recovery in Q4FY26. Investors should note the stock’s current valuation multiples reflect both depressed trailing earnings and the recent equity dilution from the Dhanuka amalgamation.
Financial Summary
Technical Snapshot
Orchid Pharma has cooled off after hitting a 52-week high of ₹1,120 in July, and is now moving sideways in the ₹985–1,036 range. The larger trend is still up — price is comfortably above its 50, 100 and 200-day averages — but the weekly RSI has turned bearish, so momentum has clearly slowed for now. As long as it holds above ₹1,140–1,150, buying on dips looks better than chasing a breakout here.
